You are here

Home » Content

Lipoprotein metabolizması hastalıkları ve tedavisine yaklaşım

Lipoprotein metabolism disorders and their treatment

Journal Name:

  • Türkiye Aile Hekimliği Dergisi

Publication Year:

  • 2010
DOI: 
doi:10.2399/tahd.10.038

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Lipoprotein metabolism disorders occupy an important place among cardiovascular diseases. Comorbid situations; such as coronary artery disease, diabetes and metabolic syndrome raise to their importance. Cholesterol and lipoprotein levels have impor¬tant roles in the formation of atherosclerosis. Having knowledge on the lipoprotein metabolism is the main aspect of the treatment plan. Although there are many highly developed drugs to decrease cholesterol levels, the treatment should be arranged according to the patients' needs. Drug intolerance constitutes a problem for the continuity of the treatment. In this review; the latest, long term, large scale randomized trials on this subject have been scrutinized. Important findings from these trials form the base of the treatment plans. The update of National Cholesterol Education Program Adult Treatment Panel-III (NCEP-ATPIII) proto¬cols are closely related with the results of these trials. It can make cholesterol treatment follow-up more effective. As a summary; for primary prevention cardiac diseases for a healthy life consists of keeping LCL cholesterol levels under 130 mg/dl, triglyceride levels under 150 mg/dl, HDL levels for men over 40 mg/dl and for women over 50 mg/dl.
Bookmark/Search this post with
Abstract (Original Language): 
Lipoprotein metabolizmas ı hastalıkları, kardiyovasküler hastalıklar içerisinde önemli bir yer tutmaktadır. Koroner arter hastalıkları, diyabet ve metabolik sendromla beraber görülmeleri önemlerini daha da arttırmaktadır. Aterosklerozun oluşum döneminde koleste¬rol ve lipoproteinlerin rolü oldukça önemlidir. Lipoprotein metabo¬lizmasının bilinmesi klinik tedavinin oluşturulmasında yardımcı bir unsurdur. Günümüzde kolesterolü düşürmek için çok gelişmiş ilaçların varlığına karşın, hastalara göre tedavinin şekillendirilmesi gerekebilir. Hastaların ilaçlara karşı toleranssızlığı etkin tedavinin devamı için sorun oluşturabilmektedir. Derlememizde bu konuda geniş boyutlu, uzun süreli yapılmış en son randomize çalışmalardan faydalanılmıştır. Bu çalışmalardan elde edilen önemli bulgular tedavilerin şekillendirilmesinde temel oluşturmaktadır. Amerikan Ulusal Kolesterol Eğitim Programı, Erişkin Tedavisi Panel 3'ün (NCEP-ATPIII) güncellenmesi randomize çalışmaların sonuçlarıyla daha yakından ilgilidir. Bu da, daha etkin kolesterol takibi uygula¬malarına yol açacaktır. Özetle, kalp hastalıklarından uzak sağlıklı bir yaşam için öncelikli korunma hedefi: LDL'nin 130 mg/dl'nin altında, trigliseridin 150 mg/dl'nin altında, HDL'nin erkeklerde 40 mg/dl'nin üstünde ve kadınlarda 50 mg/dl'nin üstünde olmasıdır.
FULL TEXT (PDF): 
PDF icon arastrmx_116859_14_pp_38-45.pdf
  • 1
38-45
  • Turkish

REFERENCES

References: 

1. World Health Organization. The World Health Report 2002; Reducing Risks Promoting Healthy Life. http://www.who.int/whr/2002/media_ centre/en/index.html adresinden 22/01/2010 tarihinde erişilmiştir.
2. Erdogan AF. Prevalance of hyperlipidemia and factors related to HDL levels in family practice. Türk Aile Hek Derg 2007; 11: 107-12.
3. Castelli WP. Epidemiology of coronary heart disease: The Framingham study. Am J Med 1984; 76: 4-12.
4. Aladag N, Ciğerli Ö, Topsever P, Filiz MT, Topallı R, Görpelioğlu S. Prevalance of obesity and ıts association with comorbidities in adult patients attending Değirmendere family practice unit: a case-control
study. Türk Aile Hek Derg2003; 7: 117-21.
5. Cingi
Mİ
. Hipolipidemik ilaçlar. Türkiye Klinikleri J Pharmacol 2004; 2:
289-94.
6. Verschuren WM, Jacobs DR, Bloemberg BP ve ark. Serum total choles¬terol and long-term coronary heart disease mortality in different cultures.
JAMA1995; 274: 131-6.
7. Durrington P, Sniderman A. Fast Facts. Hyperlipidaemia. Eds. Durrington P, Sniderman A. Oxford, Health Press, 2000; 1-17.
8. Gotto A, Pownall H. Manual of Lipid Disorders 2. baskı. Philadelphia, Williams&Wilkins, 1999; 2-10.
9. Gaw A, Packard CJ, Stepherd J. Statins: The HMG-CoA Reductase
Inhibitors in Perspective. London, Martin Dunitz, 2000; 1-19.
10. Libby P, Bonow RO, Mann DL, Zipes DP. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 8. baskı. Philadelphia, Saunders-
Elsevier, 2007; 1071-91.
11. Grundy SM, Cleeman JI, Merz NB ve ark. NCEP Report: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227-39.
12. Backer D de, Ambrosioni E, Borch-Johnsen K ve ark. Executive summa¬ry. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-10.
13. National Service Framework for Coronary Heart Disease Department of Health. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/
44
Mergen H
ve ark. | Lipoprotein metabolizması hastalıkları ve tedavisine yaklaşım
PublicationsPolicyAndGuidance/Browsable/DH_4901831 adresinden 10/01/2010 tarihinde erişilmiştir.
14. Hu FB, Bronner L, Willett WC ve ark. Fish and omega 3 fatty acid intake and risk of coronary heart disease in women. JAMA 2002; 287: 1815-21.
15. Horsmans Y. Differential metabolism of statins: importance in drug-drug interactions. Eur Heart J 1999; 1(Suppl T): T7-T12.
16. Vaughan CJ, Gotto AM, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol2000; 35: 1-10.
17. Colhoun HM, Betteridge DJ, Durrington PN ve ark. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre ran¬domised placebo-controlled trial. Lancet 2004; 364: 685-96.
18. Girman CJ, Rhodes T, Mercuri M ve ark. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93: 136-41.
19. Sarwar N, Danesh J, Eiriksdottir G ve ark. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115: 450-58.
20. Shepherd J, Barter P, Carmena R ve ark. Effect of lowering LDL choles¬terol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006; 29: 1220-6.
21. Deedwania P, Barter P, Carmena R ve ark. for the Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006; 368: 919-28.
22. Abourbih S, Filion KB, Joseph L ve ark. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med2009; 122: 962.
23. Ridker PM. Moving toward new statin guidelines in a post-JUPITER world: principles to consider. Curr Atheroscler Rep 2009; 11: 249-56.
24. Alagona P Jr. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. Am J Manag Care 2009; 15: 65-73.
25. Stein EA. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study.
Lancet 1994; 344: 1383-89.
26. Gordon DJ, Probstfield JL, Garrison RJ ve ark. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American stud¬ies. Circulation 1989; 79: 8-15.
27. Berliner JA, Navab M, Fogelman AM ve ark. Atherosclerosis: basic mecha¬nisms. Oxidation, inflammation and genetics. Circulation 1995; 91: 2488-96.
28. Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag
Care Pharm 2008; 14: 3-28.
29. Assmann G, Nofer JR. Atheroprotective effects of high density lipopro-
teins. Annu Rev Med2003; 54: 321-41.
30. Liu J, Sempos CT, Donahue RP ve ark. Non-high-density lipoprotein and very-lowdensity lipoprotein cholesterol and their risk predictive val¬ues in coronary heart disease. Am J Cardiol 2006; 98: 1363-8.
31. Dohi T, Miyauchi K, Okazaki S ve ark. Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): A follow-up study. Atherosclerosis 2009; Dec 4. [baskıda]
32. Sciahbasi A, Arcieri R, Quarto M ve ark. Impact of chronic aspirin and statin therapy on presentation of patients with acute myocardial infarction and impaired renal function. Prev Cardiol2010; 13: 18-22.
33. Reddy KJ, Singh M, Batsell RRve ark. Efficacy of combination drug pulse therapy in maintaining lipid levels in patients intolerant of daily statin use. J Clin Hypertens 2009; 11: 766-8.
34. Sujana KS, Lahey KA, Day A, Lahaye SA. Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvas-tatin monotherapy in the treatment of dyslipidemia. Lipids Health Dis
2009; 8: 56.
35. Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL: a complex process unrelated to changes in LDL: Analysis
of the VOYAGER Database. J Lipid Res 2009; Dec 2. Pubmed'den
12.01.2010
tarihind
e erişilmiştir.
36. Gibson CM, Pride YB, Hochberg CP ve ark. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
J Am Coll Cardiol2009; 54: 2290-5.
37. Margolis KL, Dunn K, Simpson LM ve ark. Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: the antihypertensive and lipid lowering to prevent heart attack trial (ALLHAT-LLT). Am
Heart J2009; 158: 948-55.
38. Massaro M, Zampolli A, Scoditti E ve ark. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angio-genic actions possibly contributing to plaque stability. Cardiovasc Res 2009; Dec 30. Pubmed'den 12.01.2010 tarihinde erişilmiştir.
39. Yang LP, Keating GM. Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia. Am J Cardiovasc Drugs 2009; 9: 401-9.
40. Sawabe M, Tanaka N, Nakahara K ve ark. High lipoprotein (a) level pro¬motes both coronary atherosclerosis and myocardial infarction: a path analysis using a large number of autopsy cases. Heart 2009; 95: 1997-2002.
41. Olivieri O, Martinelli N, Girelli D ve ark. Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associat¬ed with an enhanced plasma thrombin generation. J Thromb Haemost. Pubmed'den 12.01.2010 tarihinde erişilmiştir.

Thank you for copying data from http://www.arastirmax.com